Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

PURPOSE: Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-fr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Carmona-Bayonas, Alberto, Jiménez-Fonseca, Paula, Lamarca, Ángela, Barriuso, Jorge, Castaño, Ángel, Benavent, Marta, Alonso, Vicente, Riesco-Martínez, María del Carmen, Alonso-Gordoa, Teresa, Custodio, Ana, Sánchez Cánovas, Manuel, Hernando Cubero, Jorge, López, Carlos, Lacasta, Adelaida, Fernández Montes, Ana, Marazuela, Mónica, Crespo, Guillermo, Escudero, Pilar, Diaz, José Ángel, Feliciangeli, Eduardo, Gallego, Javier, Llanos, Marta, Segura, Ángel, Vilardell, Felip, Percovich, Juan Carlos, Grande, Enrique, Capdevila, Jaume, Valle, Juan W., García-Carbonero, Rocío
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2019
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6768612/
https://ncbi.nlm.nih.gov/pubmed/31390276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00980
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi